Laurie Alsup

Laurie Smaldone Alsup is currently serving as an Independent Director at BlackBerry Ltd., Arvinas Operations, Inc., Theravance Biopharma, Inc., Arvinas, Inc., and NDA Group AB.
She started her role at BlackBerry Ltd.
in 2015 and is still active in this position.
She began working at Arvinas Operations, Inc. as a Director and is currently still employed there.
In 2018, Dr. Alsup joined Theravance Biopharma, Inc. as an Independent Director and continues to hold this position.
She also serves as an Independent Director at Arvinas, Inc. since 2019.
Additionally, she is the Senior Vice President-Regulatory Science at NDA Group AB, a position she has held since 2016.
In her former roles, Dr. Alsup served as the President & Chief Executive Officer of Phytomedics, Inc. from 2008 to 2012.
She was an Independent Director at Humanigen, Inc. in 2015.
Dr. Alsup also served as the Lead Independent Director at Pardes Biosciences, Inc. from 2022 to 2023.
From 2013 to 2015, she was a Director at Kalobios Pharmaceuticals, Inc. She served as an Independent Director at Kinnate Biopharma, Inc. from 2020 to 2024.
From 2011 to 2016, Dr. Alsup held the position of President & Chief Scientific Officer at PharmApprove LLC.
She worked at Bristol Myers Squibb Co. from 1997 to 2007, where she held the role of VP-Corporate Strategy & Business Risk Management from 2004 to 2007.
Dr. Alsup completed her undergraduate studies at Fordham University.
She also holds a doctorate degree from Yale School of Medicine.